Comparison of diffusion-weighted imaging (DWI), perfusionweighted imaging (PWI) and MR spectroscopy (MRS) as a biomarkers for therapy response after stereotactic radiosurgery in patients with recurrent glioblastoma multiforme (GBM): our experience

摘要

Introduction: Glioblastoma (GBM) is the most common primary malignant brain neoplasm with an incidence of 4/100,000. GBM accounts for 54% of all glial tumors and 45% of all malignant central nervous system (CNS) tumors. Prognosis of patients with GBM is dismal with a median survival of 14-16 months, and a survival rate of30 and 10% at 2-5 years after the initial diagnosis, respectively. Accurate differentiation of true progression (TP) from pseudoprogression (PsP) in patients with GBMs is essential for planning adequate treatment and for estimating clinical outcome measures and future prognosis. The purpose of this study was to investigate the correlation of post-treatment quantitative advanced magnetic resonance imaging (DWI, PWI and MRS) methods in distinguishing TP from PsP in GBM patients.